CureVac GmbH, a Tübingen, Germany-based developer of therapeutic vaccines, closed a €27.6m (approximately US$ 35.25m) financing round with its major shareholder, dievini Hopp BioTech holding GmbH & Co. KG.
The proceeds will enable further clinical development of the company’s RNActive® therapeutic vaccines against solid tumours, as well as will help accelerate preclinical and clinical development of prophylactic vaccines against infectious diseases.
Currently, CureVac’s lead compound to treat prostate cancer, CV9103, is in a Phase IIa trial, with results expected in the second half of 2010.
In a separate Phase I study, the company is developing CV9201, an mRNA vaccine compound to treat non-small cell lung cancer (NSCLC).
Since its foundation, CureVac, a spin-off from Tübingen University, has raised a total of EUR 65m (US$ 83m).